Introduction
Viral hepatitis is an infection that primarily affects the liver but may also have systemic clinical manifestations. The vast majority of viral hepatitis are caused by one of five hepatotropic viruses: hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D (delta) virus (HDV), and hepatitis E virus (HEV) ( Table I ) [1] . HBV, HCV, and HDV also cause chronic hepatitis, whereas HAV does not. HEV causes acute hepatitis in normal hosts but can cause protracted and chronic hepatitis in immunosuppressed patients. 
Microbiological diagnostics of viral hepatitis
Ufuk HASDEMİR 
Hepatitis A
Serologic assays: Diagnosis of hepatitis A is most commonly confirmed by detection of specific IgM by an enzyme immune assay based techniques in a single acute-phase serum sample (Figure 1 ) (Table II, III) [1] [2] [3] . IgM Anti-HAV may be detected at the time of the first increase in alanine aminotransferase (ALT). However, specific antibody tests can be initially negative in 10% of patients who are tested soon after the onset of symptoms; testing should be repated for these patients if hepatitis A is clinically suspected. IgM Anti-HAV can be detected at least 2 days after ALT peak and remains positive in most for 3 to 6 months. It is rarely detected more than years after initial exposure. Assays for total HAV antibody are of little diagnostic value because IgG persists for many years and may be related to a past infection.
HAV antigen and nucleic acid detection: HAV or viral antigen can be detected in the stools of patients 1 to 2 weeks before symptoms develop, but such detection has little value in routine clinical diagnosis because the tests are not widely available and shedding often has stopped before the patient seeks medical attention. Nucleic-acid based techniques are seldom useful for general diagnostic purposes [1, 2] . These techniques have been used in research laboratories when a sensitive test for the presence of HAV is required. 
Hepatitis E
Hepatitis E virus may account for as much as 70% of the cases of acute viral hepatitis in endemic countries. It may cause fulminant hepatitis with case fatality rates of 0,9% to 2,8% in men and up to 20% in pregnant woman. Specific diagnosis of acute or chronic HEV infection remains a challenge. Figure 2 . has shown typical serologic and virologic course during HEV infection. Commercially available diagnostic assays vary widely in sensitivity and specificity (Table III) [1, 4] . False-positive results may be seen because of high sensitivity of these assays. There is no FDA-approved serologic or nucleic acid based techniques for diagnosis of hepatitis E. In HEV nonendemic countries, the infections of more common agents (i.e. HAV, HBV, and HCV) should first be excluded. Detection of HEV-specific IgM can be used for serologic diagnosis of acute infection in areas of low prevalence, but comperative studies have shown a wide range of assay performance. Detection of HEV-specific IgG has little impact for diagnosis of acute infection in HEV endemic countries where a majority of population has antibody from prior infection. Specificity of assays is less critical than assay sensitivity in HEV endemic countries. So rapid point-of-care IgM test may have promise for HEV diagnosis in such areas.
Detection of HEV-RNA in serum sample by RT-PCR is used as a confirmatory test for positive IgM anti-HEV results in nonendemic countries and can be used to monitor infection (Table III) . Virus isolation by tissue culture and detection of viral antigen are not appropriate methods for diagnostic purposes (Table III) . (Table II, IV) [1, 5] . Surface antigen (HBsAg) is the serologic hallmark of HBV infection and is the first marker to appear after acute infection. HBsAg appears in serum within 1 to 12 weeks, usually in 8 to 12 weeks after an acute exposure to HBV, before the onset of symptoms or elevation of serum ALT. In patients who subsequently recover, HBsAg usually becomes undetectable after 4 to 6 months, followed by development of specific IgM against core antigen (IgM anti-HBc) and then development of IgG anti-HBc. Anti-HBc can be present weeks to months before detection of anti-HBs (Figure 3) . After HBsAg clears, anti-HBs becomes detectable and persists indefinitely. Typically anti-HBs appears in serum as early as 8 months after infection (( Figure 3) (Table II, IV) . Markers of viral replication, such as HBsAg and HBV-DNA in the serum, will be present at the same time as anti-HBc. Molecular methods used for HBV-DNA detection has been shown in Table IV . Detection of HBeAg may be useful as a marker for high levels of viral replication and for relative infectivity late in the course of illness. Loss of HBV-DNA, HBeAg, HBsAg and IgM Anti-HBc and the development of antiHBe and anti-HBs all characterize immunity. The 'a' determinant is the predominant B cell epitope common to all HBV subtypes. Antibodies against to this epitope confer immunity to all HBV subtypes. Anti HBs is sufficient for protection against HBV infection.
Patients who recover from acute hepatitis B are probably not truly cured of infection because a significant number of patients will have HBV-DNA detectable by PCR many years after clinical recovery. They generally have lifelong protection from disease unless there is significant immunosuppression with loss of protective immune responses, such as in the setting of HIV, chemotherapy, or bone marrow transplantation. Table IV , has shown various serologic profiles during acute hepatitis B infection resulting with recovery.
Recovery from acute infection and Vaccination:
Recovery from acute infection and vaccination can be distinguished by testing for total anti-HBc [1, 5] . Recovery is characterized by the presence of both anti-HBs and total anti-HBc. The presence of anti-HBs is the only marker of HBV vaccination (Table IV) . 
Chronic hepatitis B
Chronic infection (high infectivity) 
Chronic hepatitis B:
Chronic hepatitis B develops in less than 5% of adults, 10% to 25% of young children, and 80% to 90% of infants after acute infection. The persistence of HBsAg for more than 6 months is a marker for development of chronic disease (Figure 4 ) [1, 5] . Patients may have additional markers of viral replication, HBeAg or HBV DNA, as well. HBeAg and HBV-DNA in serum, should be investigated for further classification of the disease and to determine the need for treatment. Among cases with chronic hepatitis B, a distinction can be drawn between those with highly replicative HBV infection (>10 5 to 10 6 IU/mL) and those with levels of replication below this threshold. In the relatively replicative phase of chronic hepatitis B, levels of HBV-DNA are high, HBeAg is detectable, HBcAg in hepatocytes is demonstrable, and clinical markers of liver injury are present. Such patients tend to have moderate to severe chronic hepatitis B. HBV-DNA level in patients having HBeAg tends to be higher than in those with HBeAg negative patients. Flares of disease activity may be due to changes in the level of baseline HBV replication. Approximately 10% to 15% of persons with highly replicative chronic hepatitis B lose markers of high replication and undergo spontaneous conversion to a relatively low replicative state characterized by limited infectivity and liver injury and loss of HBeAg and of detectable HBcAg in hepatocytes. Such patients tend to have clinically mild chronic hepatitis or are even inactive carriers of the virus (Table IV) . Additional information regarding HBV-DNA and its' detection have been shown in Box 1, Table IV and Table V [1, 6] . 4. HBV-DNA measurement is also useful in cases of fulminant hepatitis, where there may be undetectable levels of HBsAg.
5. HBV-DNA testing is also indicated in patients in whom there may be false-negative HBsAg, which occurs due to mutants in the surface protein. Table I . has shown typical virologic characteristics of HCV infection. There are at least six major genotypes or clades of hepatitis C virus (HCV). The high level of virion turnover coupled with the absence of proofreading by the NS5B polymerase results in generation of quasi-species in an infected individual. The incubation period of hepatitis C is from 15 to 160 days (mean of 60 days). Viremia peaks 8 to 12 weeks after infection and then plateaus or drops to lower levels and persists in 85% to 90% of individuals ( Figure 5 ) [1, 9] . Simplified diagnostic approach in patients with acute hepatitis C has been shown in Table II . After infection, HCV-RNA can be detected within days of exposure. HCV-RNA is found in blood, saliva, tears, seminal fluid, ascitic fluid, and cerebrospinal fluid. The diagnosis of HCV infection is based principally on detection of antibodies to recombinant HCV polypeptides and by assays for HCV-RNA [1, 9, 10] . There have been several generations of EIAs that measure antibodies against NS4, core, NS3, and NS5 sequences. The sensitivity of the third-generation EIA is 97%, and it can detect HCV antibody within 6 to 8 weeks of exposure. These assays determine either past or recent HCV infection, not immunity. Assays for IgM HCV antibodies are not clinically useful. In the past, supplemental serologic testing such as with the recombinant immunoblot assay has been used to improve the specificity of the screening tests. However, supplemental antibody assays are no longer commercially available in the United States. Today, HCV testing recommendations generally call for screening for HCV antibodies followed by RNA testing [1, 9, 10] . In acute HCV infection or immunosuppressed states, a negative anti-HCV EIA result does not exclude HCV infection.
HCV-RNA testing is helpful if seronegative acute HCV infection is suspected because HCV-RNA can be detected within 2 to 3 days after an exposure, while antibodies to HCV are detectable an average of 7 to 8 weeks later. HCV-RNA testing can also be used to screen for HCV infection in persons with negative anti-HCV EIA results who are known to have conditions associated with diminished antibody production, such as HIV infection and hemodialysis. Various molecular techniques, including reverse-transcription PCR (RT-PCR), real-time PCR, transcription-mediated amplification (TMA), and branched DNA (bDNA) are used for detection of HCV-RNA (Table V) . Real-time PCR and TMA assays quantify virus across a wide range and have comparable sensitivity (10 to 50 IU/mL) to qualitative assays. In persistently infected persons not receiving treatment, HCV-RNA levels tend to remain stable (within one-half log 10 ) over years. In the absence of treatment, there is little need to repeat HCV-RNA tests frequently.
The HCV core antigen titer corresponds closely with the HCV-RNA level, but the test is not widely used in practice [1, 9] .
Determination of HCV genotype may be useful in predicting the response to therapy (Box 5). 
